OM
URGN icon

Opaleye Management’s UroGen Pharma URGN Stock Holding History

Opaleye Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.7M Buy
1,430,000
+1,161,577
+433% +$23.3M 3.39% 8
2025
Q4 		$6.29M Buy
+268,423
New +$5.82M 0.83% 28
2025
Q1 		– Sell
-220,000
Closed -$2.34M – 54
2024
Q4 		$2.34M Sell
220,000
-184,100
-46% -$2.2M 0.41% 30
2024
Q3 		$5.13M Sell
404,100
-7,900
-2% -$117K 0.86% 24
2024
Q2 		$6.91M Buy
412,000
+142,000
+53% +$2.02M 1.58% 21
2024
Q1 		$4.05M Sell
270,000
-50,000
-16% -$817K 0.88% 30
2023
Q4 		$4.8M Hold
320,000
– – 1.28% 22
2023
Q3 		$4.48M Sell
320,000
-250,000
-44% -$4.01M 1.46% 19
2023
Q2 		$5.9M Buy
570,000
+65,000
+13% +$717K 1.41% 19
2023
Q1 		$4.67M Buy
505,000
+16,344
+3% +$150K 1.4% 25
2022
Q4 		$4.33M Buy
488,656
+91,156
+23% +$863K 1.51% 21
2022
Q3 		$3.31M Buy
397,500
+158,830
+67% +$1.31M 1.37% 20
2022
Q2 		$1.96M Buy
+238,670
New +$1.64M 0.88% 28

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Opaleye Management's URGN Position: Q1 2026 in Review

Opaleye Management increased its UroGen Pharma (URGN) stake by 433% in Q1 2026, buying an estimated $23.3M and bringing the position to 1,430,000 shares worth $25.7M. The position accounts for 3.39% of the portfolio, ranked #8.

Opaleye Management first reported a position in URGN in Q2 2022 and has held it in 13 quarters since. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Opaleye Management held 1,430,000 shares of UroGen Pharma worth $25.7M as of Q1 2026.
  • Opaleye Management bought 1,161,577 UroGen Pharma shares in Q1 2026, an estimated $23.3M.
  • UroGen Pharma made up 3.39% of Opaleye Management's portfolio in Q1 2026, its #8 holding.
  • Opaleye Management first reported a position in UroGen Pharma in Q2 2022 and has held it in 13 quarters since.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.